Precertification required for listed products

Precertification is required for the listed IVIG and SCIG products for Aetna participating providers and members in applicable plan designs; contact (866) 752-7021 or fax (888) 267-3277 and submit a Statement of Medical Necessity (SMN) as part of precertification.

• Applies to listed IVIG products (Asceniv, Bivigam, Flebogamma DIF/10%, Gammagard Liquid/S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Panzyga, Privigen).
• Applies to listed SCIG products (Cutaquig, Cuvitru, Hizentra, HyQvia, Xembify).

HCPCS product code coverage contingent on criteria

HCPCS J‑codes for specific IVIG/SCIG products are covered only when the policy selection/coverage criteria are met; use the appropriate product J‑code for billing.

• Examples: J1459, J1551, J1554, J1555, J1556, J1557, J1558, J1559, J1561, J1566, J1568, J1569, J1572, J1575, J1576, J1599.
• Coverage contingent on meeting the clinical criteria in the policy for the requested indication.

Prior authorization: indication and product justification

Prior authorization requests must justify IVIG/SCIG by specifying the clinical indication (FDA‑approved or compendial) and include relevant clinical documentation and rationale for product selection.

• Document diagnosis, prior therapies, and why the selected product is appropriate for the patient.
• If deviating from formulary or prior product, provide justification and supporting clinical details.

Prior authorization recommended for off-label/severe infectious indications

For off‑label or severe infectious uses (e.g., severe/recurrent C. difficile, suspected neonatal infection) prior authorization should include documentation of disease severity, prior standard therapies tried, and justification referencing limited/inconsistent evidence.

• Provide prior antibiotic/standard therapy details and timing before IVIG.
• Cite trial-level evidence or rationale given mixed case‑series and trial findings.

Neuromuscular indications

For neuromuscular indications (GBS, CIDP, MG), support prior authorization requests with guideline or evidence summaries demonstrating indication‑specific benefit (e.g., AAN guidance for GBS/CIDP).

• Indicate whether use is for acute exacerbation, short-term therapy, or maintenance and document prior treatments as applicable.
• For MG, document indication for rapid induction (crisis, pre‑operative) or refractory disease after standard therapies.

IVIG for neonatal isoimmune hemolytic disease — justify with study quality

When requesting IVIG for neonatal isoimmune hemolytic disease, include trial‑level evidence and an assessment of study quality because randomized trials have mixed risk‑of‑bias and low‑quality findings.

• Cite relevant systematic reviews/meta-analyses and note whether low‑risk‑of‑bias studies show benefit.
• Provide clinical context (e.g., need to reduce exchange transfusion) and prior management.

PA for rare or off‑label IVIG indications

Prior authorization is appropriate for prophylactic or repeated IVIG use in rare disorders (e.g., systemic capillary leak syndrome) or other off‑label indications and should document disease severity and prior therapies.

• Provide disease history, frequency of attacks or transfusions (if applicable), and specialist recommendation.
• Cite supporting cohort or case‑series evidence when available.

Livedoid vasculopathy — prior authorization suggested

For livedoid vasculopathy, prior authorization should require documentation of refractory disease and prior therapies tried, and reference case‑series regimens (commonly 2 g/kg every 4 weeks) when used.

• Document prior medical and procedural treatments and duration of refractory disease.
• Include treatment regimen details and response history from specialty care notes.

Necrotizing autoimmune myopathy — prior authorization suggested

For necrotizing autoimmune myopathy, include biopsy, CK, antibody status, prior/immediate steroid response, and rationale for adding IVIG in the prior authorization submission.

• Provide multi‑agent immunosuppression history and objective muscle testing/biopsy results.
• Document prior corticosteroid response and reasons for escalation to IVIG.

Prior authorization — document prior therapies and IgG levels

Prior authorization should document prior standard management (e.g., reduction of immunosuppression for BK virus nephropathy) and present objective IgG levels (e.g., IgG <400 mg/dL when cited) or evidence of B‑cell aplasia when used as rationale for IVIG.

• Include prior therapy steps taken (immunosuppression adjustments) before IVIG consideration.
• Report laboratory values supporting hypogammaglobulinemia (laboratory reference ranges preferred).

Evidence-based prior authorization requirement

Prior authorization for off‑label or low‑evidence indications should cite relevant clinical evidence (RCTs, meta‑analyses, guideline statements) supporting the requested use and explain the clinical rationale when evidence is limited.

• Attach pertinent trial citations or guideline excerpts referenced in the request.
• Explain why standard therapies are unsuitable or have failed, if applicable.

Prior authorization for IVIG in AGID

For autoimmune gastrointestinal dysmotility (AGID), prior authorization must include objective motility testing or manometry results and autoimmune serology/personal or family autoimmune history to justify an IVIG diagnostic or therapeutic trial.

• Provide scintigraphy or manometry reports showing objective dysmotility.
• Document serologic autoimmune evidence or relevant family history and prior therapy attempts.

Prior authorization for MIS-C therapy

Prior authorization for MIS‑C immunotherapy should include documentation of diagnostic criteria fulfillment, clinical severity indicators (need for inotropes, ventilation, LV dysfunction), and the chosen initial regimen (IVIG alone vs IVIG plus glucocorticoids) with justification based on comparative observational data.

• Document WHO diagnostic criteria, hemodynamic status, and laboratory inflammatory markers.
• State rationale for combination therapy when used (observational data favoring IVIG plus glucocorticoids).

Prior authorization for IVIG

Prior authorization is required for IVIG use and requests for indications listed as experimental/investigational in the policy appendix will be denied unless sufficient medical necessity documentation and supporting evidence for an accepted indication are provided.

• If an indication appears on the appendix investigational list, provide high‑quality supporting evidence to justify exception.
• Note that impaired pneumococcal vaccine response (age ≥2) is an appendix‑specified indication but excludes hospital‑initiated therapy.

Prior authorization for IVIG/SCIG

IVIG/SCIG requests for indications listed as experimental/investigational are not supported by policy and require prior authorization documentation of medical necessity, including diagnosis and supporting evidence (FDA‑approved indication when applicable).

• Attach prescribing information if claiming an FDA‑approved indication for the product.
• For off‑label indications on the investigational list, include strong evidence and specialist rationale.

Prior authorization — none stated

No prior authorization codes or procedural requirements are specified in the references section; these chunks contain citations only and do not define authorization rules.

• References list does not substitute for precertification requirements described elsewhere in the policy.

Prior authorization — references only

This references segment contains citation entries only and does not specify prior authorization rules; do not rely on these chunks for procedural requirements.

• Use the policy's authorization/prior‑auth sections (see chunk 3 and relevant prior_auth entries) for actual precertification instructions.

Prior therapy requirements

For indications like myasthenia gravis, prior therapy documentation is required: providers must show trials and failures of standard therapies (e.g., corticosteroids, azathioprine, cyclosporine, mycophenolate, rituximab) or state contraindications before chronic IVIG is considered.

• Document duration and response to each prior agent and reasons for discontinuation or intolerance.
• For refractory MG, show trial of ≥2 standard therapies and objective confirmation of diagnosis.

Step-down/cessation consideration

When conventional therapy is effective, continued IVIG administration is not considered medically necessary; if continuation is requested, document ongoing clinical need and benefit (e.g., infection frequency reduction or maintained functional improvement).

• Provide data showing reduction in bacterial infections or maintenance of IgG trough levels as applicable.
• Prescribers should plan re‑evaluation and dose adjustments as part of continuation documentation.

Step therapy before chronic IVIG for myasthenia gravis

Before approving chronic maintenance IVIG for myasthenia gravis, document trials of standard maintenance therapies (acetylcholinesterase inhibitors, steroids, thymectomy when indicated, and steroid‑sparing agents) and show inadequate response or contraindication to those therapies.

• For crisis or unstable patients, IVIG or plasmapheresis is appropriate; routine maintenance IVIG requires strong justification.
• Include timing and quantitative measures of prior therapeutic responses.

MG: induction therapy considerations

For MG induction (rapid effect) uses of IVIG, document prior symptomatic treatment and whether IVIG is being used for acute exacerbation, pre‑operative stabilization, or crisis management as an alternative to plasmapheresis.

• Provide dates and clinical measures showing need for rapid induction (e.g., respiratory compromise, bulbar symptoms).

Step therapy for severe dermatologic photodermatoses

For severe dermatologic photodermatoses (e.g., idiopathic solar urticaria), document failure or intolerance of standard therapies (antihistamines, phototherapy, cyclosporine) before considering IVIG.

• Include prior therapy durations and objective response assessments.
• Provide specialist dermatology documentation when available.

Step therapy considerations for Evans syndrome

For Evans syndrome, authorization for repeated or maintenance IVIG should document prior corticosteroid use and other standard therapies, since IVIG is generally used acutely and maintenance benefit is limited.

• Describe prior response to IVIG and duration of effect to justify any repeat dosing.
• Consider alternative immunosuppressive strategies if IVIG response is transient.

Ocular myasthenia gravis — step approach

For ocular myasthenia gravis, document trials of pyridostigmine and steroids (or steroid‑sparing agents) and only consider IVIG when severe generalized MG features or debilitating bilateral ptosis persist despite standard therapy.

• Provide ophthalmologic/neurophysiologic confirmation and prior treatment details.
• IVIG is rarely required for isolated ocular disease.

BKPyVAN — immunosuppression modification first

For BK virus nephropathy (BKPyVAN), step therapy requires prior reduction or discontinuation of antimetabolites and/or calcineurin inhibitor dose adjustment before considering adjunctive IVIG; document those measures and IgG level if hypogammaglobulinemia is claimed (e.g., IgG <400 mg/dL).

• Provide records of immunosuppression modification and virologic/biopsy data.
• If proposing IVIG due to IgG deficiency, include laboratory evidence with reference ranges.

Step therapy / alternative therapies

For indications with limited evidence, document consideration and trials of alternative guideline‑supported therapies (e.g., antibiotics or CBT for PANDAS; supportive care for HFMD) before IVIG is requested.

• Explain why alternatives are unsuitable or have failed.
• Attach relevant guideline or study citations supporting the step‑therapy sequence.

Consideration of combination therapy in MIS-C

Observational data suggest IVIG plus glucocorticoids may reduce cardiovascular dysfunction and treatment failure in MIS‑C; document rationale for combination therapy in the prior authorization and include severity indicators supporting initial use of combination therapy.

• Include evidence of cardiovascular involvement (LV dysfunction, need for inotropes) to support combination therapy.
• If IVIG alone is proposed for mild MIS‑C, document absence of cardiovascular dysfunction and reason to avoid steroids.

MIS-C treatment sequencing

Clinical guidance cited suggests initial therapy for most MIS‑C patients is IVIG plus glucocorticoids rather than IVIG alone; prior authorization should indicate whether this combined approach is used and justify exceptions (e.g., mild disease without cardiac dysfunction).

• Document diagnostic criteria, inflammatory markers, and hemodynamic status.
• Describe anticipated escalation plan if no improvement within ~24 hours.

Step therapy not specified

No step therapy specifics are provided in the references segment; consult product prescribing information and the policy's criteria sections for replacement/alternate therapy requirements and step‑therapy expectations.

• References-only chunks do not define operational step therapy rules.
• Use the policy’s clinical criteria for condition‑specific step requirements.

Step therapy not specified (references)

These reference chunks contain citations only and do not specify step therapy requirements or authorization procedures; they are for background/reference purposes.

• Do not use reference‑only chunks as substitute for authorization or documentation instructions.

Precertification and SMN

For precertification, providers must use the contact information and SMN forms provided by Aetna to submit requests; precertification is required for listed IVIG and SCIG products and site‑of‑care policies apply to infusions.

• Call (866) 752-7021 or fax (888) 267-3277 for precertification and submit the Statement of Medical Necessity (SMN) form.
• Apply Site of Care Utilization Management Policy for infusion location considerations.

Continuation documentation

Continuation requests must document reduction in infection frequency or maintenance of clinical improvement (as applicable) and include IgG trough monitoring at least yearly or prescriber plans for dose re‑evaluation.

• Show objective clinical benefit (fewer infections) since initiation or IgG trough levels maintained at/above lower normal for age.
• If continuing, include prescriber's plan to reassess dose and frequency as appropriate.

Dosing source

Dosing and administration must follow each product’s prescribing information; include product‑specific dosing details in documentation and billing.

• Refer to the manufacturer prescribing information for dose, frequency, and administration guidance.
• Ensure billed J‑code matches the product and dose administered.

Required clinical documentation

Required clinical documentation for authorization should include baseline and interval renal function (BUN, serum creatinine), urine output, continuous vital‑sign monitoring during infusion, indication (FDA‑approved or compendial), product selected and rationale, and ongoing clinical monitoring notes.

• Provide renal function tests and hydration status to mitigate renal risk.
• Document infusion rates and vital signs; infusion rate should not exceed 4 mg/kg/min.

Antibody titers and fetal/neonatal monitoring

When IVIG is used in maternal autoantibody‑mediated fetal cardiomyopathy, include maternal and neonatal antibody titers and detailed fetal/neonatal monitoring data; prospective trial evidence and titer evaluation are recommended in supporting requests.

• Submit maternal anti‑Ro/anti‑La titers and fetal echocardiography reports.
• Cite available cohort data and note the need for prospective randomized evidence.

Support for neonatal IVIG requests

Requests for neonatal IVIG (suspected neonatal sepsis) should cite randomized trial evidence (INIS) and Cochrane findings; documentation must include indication, prior antibiotic therapy, and justification referencing trial quality because large RCTs showed no routine benefit.

• Attach INIS trial citation and summarize relevance to the case.
• Explain why case differs from INIS if requesting IVIG for neonatal infection.

Provide supporting immune-reconstitution metrics for selective prophylactic IVIG

For selective prophylactic IVIG after allo‑SCT, provide immune‑reconstitution metrics used in studies (e.g., IgG <4 g/L, NK <100/µL, CD4 <100/µL, presence of GVHD) when claiming similar selective use; attach study or algorithm evidence.

• Include monthly immune monitoring data and GVHD status if using algorithmic prophylaxis.
• Cite the study showing no reduction in CMV incidence when using the selective algorithm.

Documentation for rare/compassionate use

When IVIG is requested for rare or compassionate uses (e.g., Clarkson disease prophylaxis, adjunct to IUT for RhD alloimmunization), document disease severity, prior therapies, attack frequency or transfusion history, and cite the limited cohort/series evidence supporting use.

• Include specialist recommendation and frequency/severity metrics that justify exception use.
• Attach cohort studies or pilot data supporting the proposed regimen.

Asymptomatic kidney transplant recipients with dnDSA — documentation

For asymptomatic kidney transplant recipients with de‑novo donor‑specific antibodies (dnDSA), document timing of dnDSA (within first year), baseline allograft biopsy results, and prior treatment strategy because pilot data did not show prevention of acute ABMR with pre‑emptive high‑dose IVIG.

• Provide biopsy reports and dnDSA timing/levels; state prior or planned interventions.
• Cite the pilot study showing lack of prevention of ABMR with IVIG alone.

BKPyVAN — documentation

For BKPyVAN, documentation must show prior reduction of immunosuppression and include current IgG level if severe hypogammaglobulinemia is the rationale (e.g., IgG <400 mg/dL); IVIG is adjunctive and considered only after standard step‑therapy measures.

• Attach records of immunosuppression changes, virologic monitoring, and renal biopsy data.
• Include IgG laboratory values with reference ranges when hypogammaglobulinemia is cited.

Objective lab and prior therapy documentation

Provide objective laboratory measures and prior therapy documentation when requesting IVIG for hypogammaglobulinemia‑related indications (e.g., IgG <400 mg/dL in BKPyVAN, evidence of CAR‑T–related B‑cell aplasia), and reference the policy thresholds where applicable.

• Include IgG levels, timing relative to transplant or CAR‑T therapy, and documented infection history.
• Attach lab reference ranges or the laboratory’s reported normals.

Documentation for autoimmune GI dysmotility

For suspected autoimmune GI dysmotility, include objective motility testing (scintigraphy or manometry), serologic autoimmune evidence or personal/family autoimmune history, and details of any diagnostic/therapeutic immunotherapy trial (agent, dose, duration, pre/post assessments).

• Provide scintigraphy/manometry reports and autoantibody panels when available.
• Document symptomatic and objective response assessments after the trial period (6–12 weeks in cited series).

Documentation for AGID diagnostic immunotherapy trial

For AGID diagnostic immunotherapy trials, document objective evidence of GI dysmotility, autoimmune markers or relevant history, and a specified trial plan (agent, dose, duration, objective pre/post measures) to support the diagnostic/therapeutic use of IVIG.

• Include baseline and follow‑up scintigraphy or manometry results.
• State planned duration (e.g., 6–12 week trial) and outcome measures to assess response.

Documentation for MIS-C immunotherapy

For MIS‑C immunotherapy requests, document fulfillment of diagnostic criteria, the chosen initial immunomodulatory regimen (IVIG alone versus IVIG plus glucocorticoids), and clinical severity measures (need for inotropes, ventilation, LV dysfunction) to justify regimen selection.

• Provide WHO criteria documentation and inflammatory marker trends (CRP, D‑dimer, ferritin).
• If proposing IVIG plus steroids, include evidence of cardiovascular involvement or rationale for combined therapy.

Required documentation for vaccine-response indication

For the impaired pneumococcal polysaccharide vaccine response indication (age ≥2 years), include documented impaired antibody response results and laboratory reference ranges; note that therapy initiated in the hospital setting is excluded from this appendix entry.

• Submit pneumococcal serology results with the laboratory’s reference ranges.
• Confirm patient age ≥2 years and that therapy is outpatient‑initiated per appendix guidance.

Document FDA product and indication

When proposing therapy, document the FDA‑approved product and specific indication per the product labeling (brand and indication) to support medical necessity and correct billing.

• Attach prescribing information or product labeling showing the claimed FDA indication.
• Ensure the billed J‑code corresponds to the product administered.

All other indications considered experimental/investigational

All other indications not listed in the policy are considered experimental and investigational and may be denied; consult the appendix investigational list and do not submit routine IVIG requests for conditions on that list without strong supporting evidence.

• If the requested indication appears on the investigational appendix, include high‑quality evidence to justify exception.
• Examples of investigational entries are enumerated in the appendix (chunks 217–220).

Experimental/Investigational indications

Use of IVIG/SCIG for clinical conditions not listed as covered is considered experimental/investigational and may be denied; providers should avoid requests for these indications without high‑quality supporting evidence.

• The policy’s Experimental and Investigational section states these uses are not established.
• Refer to the appendix for the full list of investigational conditions.

Monitoring and infusion rate risks

Failure to document monitoring (vital signs, renal function, urine output) or administering IVIG above the recommended infusion rate (maximum 4 mg/kg/min) may raise safety concerns and could trigger denial or requests for additional information.

• Document continuous vital‑sign monitoring and infusion rate in infusion records.
• Provide baseline and interval BUN/serum creatinine and urine output data for patients at renal risk.

Potential denial triggers from NAC recommendations

Expert panel (NAC) recommendations noted routine IVIG was not recommended for many hematologic conditions and IVIG was contraindicated for heparin‑induced thrombocytopenia; routine use contrary to these recommendations may trigger denials.

• Provide justification for use in hematologic conditions not recommended by the NAC panel.
• If indication is among those not recommended, include life‑threatening context and strong supporting evidence.

Prophylactic IVIG after allo-SCT

Selective prophylactic IVIG after allogeneic stem cell transplant did not reduce CMV incidence in a study using algorithmic immune thresholds and therefore prophylactic use for this indication may be denied as not effective.

• If claiming prophylactic IVIG benefit post‑allo‑SCT, include immune‑reconstitution metrics and trial justification.
• Cite the study of 79 patients showing no significant reduction in CMV incidence.

Neonatal infection — routine IVIG not supported

Routine administration of IVIG to prevent mortality in infants with suspected or proven neonatal infection is not supported by the large INIS trial and such requests may be denied absent new high‑quality evidence.

• Attach INIS trial evidence when neonatal infection is cited and explain why the case differs if requesting IVIG.
• Routine prophylactic IVIG for neonatal sepsis is not recommended per INIS.

ABO hemolytic disease — routine IVIG not supported

Use of IVIG for ABO hemolytic disease of the newborn did not reduce phototherapy or hospital duration in comparative studies; routine IVIG for this indication may be denied without convincing supportive evidence.

• Provide trial citations and study‑quality assessment if requesting IVIG for ABO HDN.
• Document why standard phototherapy/exchange transfusion approaches are insufficient.

Viral myocarditis — limited evidence

Randomized trial evidence does not support routine IVIG for adults with presumed viral myocarditis; requests lacking higher‑quality supportive evidence could be denied.

• Attach trial data if claiming benefit for viral myocarditis; note limitations and risk‑of‑bias.
• Provide pediatric vs adult distinction and justify adult use specifically.

Neonatal alloimmune HDN — limited/uncertain evidence

Evidence for IVIG benefit in neonatal alloimmune hemolytic disease is low‑quality and blinded trials did not show benefit; payers may deny IVIG for alloimmune HDN when only low‑quality or unblinded evidence is provided.

• Provide high‑quality blinded trial evidence to overcome policy concerns.
• Document clinical context that may justify exception use.

Evidence gaps may trigger denial

Evidence gaps for conditions such as PANDAS/PANS and SJS/TEN may trigger denial; providers must submit robust RCT or meta‑analytic evidence when requesting IVIG for such indications.

• For PANDAS/PANS, cite the double‑blind RCTs and systematic reviews and explain clinical justification.
• For SJS/TEN, note conflicting meta‑analyses and guideline recommendations against routine IVIG.

IMIG limitations

Intramuscular immunoglobulin (IMIG) has practical and safety limitations (pain, dosing limits, local tissue injury, inability to attain normal serum IgG) and chronic replacement via IMIG is unlikely to be supported; such requests may be denied.

• IMIG is used only for short‑term prophylaxis in specific outbreak or travel scenarios, not chronic replacement.
• Document rationale if attempting IM route for chronic therapy; expect denial without strong justification.

IVIG investigational indications (denial trigger)

Use of IVIG for any condition listed as experimental/investigational in the appendix will generally trigger denial unless compelling evidence is provided; review the appendix list and avoid routine requests for listed conditions without strong supporting data.

• Appendix lists numerous investigational conditions; check entries before submitting authorization requests.
• If requesting exception, include high‑quality evidence and specialty consultation notes.

Denial risk for investigational indications

Requests for IVIG for conditions on the experimental/investigational list are subject to denial; ensure the indication is not on the appendix or provide robust supporting evidence to justify approval.

• Provide literature citations and rationale demonstrating expected benefit for the specific patient.
• If indication is not listed as covered, expect denial absent exceptional documentation.

References-only note (no authorization rules)

This references section contains citation entries only and does not specify authorization or denial triggers; do not rely on these reference‑only chunks for procedural requirements.

• Use policy sections (authorization, documentation, criteria) for actionable requirements rather than reference lists.